Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk3207. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 7/20 | 1.00 |
| ▸ | CALCA | P06881 | 1/20 | 1.00 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.60 |
| ▸ | CALCR | P30988 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk3207 SCHEMBL13599294 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCARAMP3CALCR | |
| Mk3207 SCHEMBL29359897 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCARAMP3CALCR | |
| Mk3207 SCHEMBL31231899 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCARAMP3CALCR | |
| Mk3207 SCHEMBL13599187 | 1.00 | CALCRL (1.00) | CALCRLRAMP1CALCARAMP3CALCR | |
| Mk3207 SCHEMBL1274245 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13599180 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13599405 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13599208 | 0.99 | CALCRL (0.99) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13599243 | 0.94 | CALCRL (0.88) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13599417 | 0.94 | CALCRL (0.88) | CALCRLRAMP1CALCARAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366286-A1 | COMPOUNDS FOR TREATING SEPSIS | Keller, Johannes (DE) | 2018-08-29 | — | — | EP | claimed |
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-07-05 | — | — | US | claimed |
| US-20260102396-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-20220249471-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3366286-A1 | COMPOUNDS FOR TREATING SEPSIS | Keller, Johannes (DE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-07-05 | — | — | US | disclosed |
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-07-05 | — | — | US | disclosed |
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-07-05 | — | — | US | disclosed |
| US-8394767-B2 | Methods of treating cancer using the calcitonin-gene related peptide (“CGRP”) receptor antagonist CGRP8-37 | UNIVERSITY OF ROCHESTER (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110189205-A1 | METHODS OF TREATING CANCER USING AN AGENT THAT MODULATES ACTIVITY OF THE CALCITONIN-GENE RELATED PEPTIDE (\"CGRP\") RECEPTOR | UNIVERSITY OF ROCHESTER (US) | 2011-08-04 | — | — | US | disclosed |
| US-7629338-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7625901-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625901-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| WO-2008020902-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007133491-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102396-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | CALCRL, CALCA, P2RY10 | CALCRL 1/4885RAMP1 228/4885CALCA 2/4885 |
| US-20180185360-A1 | CGRP RECEPTOR ANTAGONIST COMPOUNDS FOR TOPICAL TREATMENT OF SKIN DISORDERS | CALCRL, MRGPRX1, IL1RN | CALCRL 1/4885RAMP1 24/4885CALCA 8/4885 |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | CALCRL 2/4885RAMP1 75/4885CALCA 16/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | CALCRL 2/4885RAMP1 70/4885CALCA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.